Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 120

Sort by

Sort Order Select

Journal Articles

Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study

Michael Wang, Yuqin Song, Olivier Hermine, Yuerong Shuang, Wojciech Jurczak, João Samuel de Holanda Farias, Carolina Mahuad, Muhit Ozcan, Ron D. Jachimowicz, Tianlei Chen, Elena Ivanova, Xiaotong Li, Gabriel Man, Priscille Bourquelot, Remus Vezan, Toby Eyre

Blood (2025) 146 (Supplement 1): 663.

https://doi.org/10.1182/blood-2025-663

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Blood (2025) 146 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2025-3587

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood (2025) 146 (Supplement 1): 886.

https://doi.org/10.1182/blood-2025-886

Published: 2025

Journal Articles

Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up

Michael Wang, Jonas Paludo, João Samuel de Holanda Farias, Diego Villa, Cecily Forsyth, Ellie John, Menglu Che, Harneet Arora, Craig Delury, Victoria Otero, Yuqin Song

Blood (2025) 146 (Supplement 1): 885.

https://doi.org/10.1182/blood-2025-885

Published: 2025

Journal Articles

Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma

Pier Luigi Zinzani, Jiri Mayer, Christopher Flowers, Fontanet Bijou, Ana C. De Oliveira, Yuqin Song, Qing-Yuan Zhang, Marco Brociner, Krimo Bouabdallah, Peter S. Ganly, Huilai Zhang, Sam Yuen, Marek Trneny, Rebecca Auer, Sha Huang, Jiayi Shen, Jamie Hirata, Judith Trotman

Blood (2025) 146 (Supplement 1): 227.

https://doi.org/10.1182/blood-2025-227

Published: 2025

Journal Articles

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Yan Huang, Yanyan Liu, Hongming He, Zhiming Li, Ningjing Lin, Ou Bai, Caixia Li, Xiaobo Wang, Yajun Li, Xingli Zhao, Huijing Wu, Xiaorui Fu, Zhihua Yao, Jiuyang Zhang, Ying Chen, Wei Meng, Zhuli Wu, Wenzhi Tian, Yuqin Song

Blood (2025) 146 (Supplement 1): 5358.

https://doi.org/10.1182/blood-2025-5358

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

CELF2-deficient mutations promote B-cell lymphoma development by inducing a germinal center B-cell fate

Tao Pan, Yuqin Song, Xiaomin Wang

Blood (2025) 146 (Supplement 1): 5038.

https://doi.org/10.1182/blood-2025-5038

Published: 2025

Journal Articles

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Blood (2025) 146 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2025-1957

Published: 2025

Journal Articles

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory follicular lymphoma

Yuqin Song, Ye Guo, Qingqing Cai, Haisheng Liu, Mingxia Wang, Wenrong Huang, Mingzhi Zhang, Lanfang Li, Yanyan Liu, Yuerong Shuang, Zengjun Li, Cuizhen Niu, Andrew Chow, Jingxia Chen, Yan Xie

Blood (2025) 146 (Supplement 1): 5372.

https://doi.org/10.1182/blood-2025-5372

Published: 2025

Journal Articles

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Ningjing Lin, Keshu Zhou, Quande Lin, Lihua Qiu, Zhiming Li, Wei Yang, Yuerong Shuang, Jian Zhang, Hongyan Tong, Hongmei Jing, Peiqi Zhao, Jing Liu, Hong Li, hongli zhang, Liqiang Fu, Gang Lu, Yuqin Song

Blood (2025) 146 (Supplement 1): 5368.

https://doi.org/10.1182/blood-2025-5368

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2025-3896

Published: 2025

Journal Articles

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory diffuse large B-cell lymphoma

Yuqin Song, Qingqing Cai, Ye Guo, Haisheng Liu, Mingxia Wang, Wenrong Huang, Mingzhi Zhang, Yanyan Liu, Lanfang Li, Yuerong Shuang, Zengjun Li, Cuizhen Niu, Lin-Chi Chen, Jingxia Chen, Yan Xie

Blood (2025) 146 (Supplement 1): 3740.

https://doi.org/10.1182/blood-2025-3740

Published: 2025

Journal Articles

Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma (MCL) after receiving covalent bruton tyrosine kinase inhibitors (cBTKi) in China

Ningjing Lin, Yuqin Song, Xue Zhang, Guangdong Xie, Xiao Ma, Jun Zhu

Blood (2025) 146 (Supplement 1): 2704.

https://doi.org/10.1182/blood-2025-2704

Published: 2025

Journal Articles

Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy

Eliza Hawkes, Clementine Sarkozy, Yuqin Song, Muhit Ozcan, Franck Morschhauser, Alex Herrera, Alev Akyol, Parth Rao, Antonia Di Micco, Adrien Petel, Serena Perna, Charalambos Andreadis

Blood (2025) 146 (Supplement 1): 3615.

https://doi.org/10.1182/blood-2025-3615

Published: 2025

Journal Articles

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Blood (2025) 146 (Supplement 1): 3614.

https://doi.org/10.1182/blood-2025-3614

Published: 2025

Journal Articles

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)

Richard Miller, Ryan Wilcox, John Reneau, Costas Yannakou, Won Seog Kim, Tatyana Feldman, Youn-H Kim, Michael Khodadoust, Dejan Radeski, Robin Gasiorowski, Dok Hyun Yoon, Yuqin Song, Andrew Hotson, Suresh Mahabhashyam

Blood (2025) 146 (Supplement 1): 778.

https://doi.org/10.1182/blood-2025-778

Published: 2025

Journal Articles

Linperlisib Combined with CHOP Regimen Followed By Autologous Hematopoietic Stem Cell Transplantation and Linperlisib Monotherapy Maintenance for Newly Diagnosed Nodal T-Follicular Helper Cell Lymphoma Patients: A Phase II Trial

Weiping Liu, Yao Liu, Zengjun Li, Shujuan Wen, Zhihua Zhang, Liqun Zou, Ming Jiang, Liping Dou, Ou Bai, Jie Yu, Yue Wang, Jie Chen, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 6389.

https://doi.org/10.1182/blood-2024-199929

Published: 2024

Journal Articles

Safety and Efficacy of Iruplinalkib for Patients with Relapsed or Refractory (r/r) ALK+ Lymphoma: A Phase II Trial

Yue Wang, Fang Wei, Wanli Wang, Linjun Zhao, Jie Chen, Yuqin Song, Jun Zhu, Weiping Liu

Blood (2024) 144 (Supplement 1): 6386.

https://doi.org/10.1182/blood-2024-207002

Published: 2024

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up

Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma

Phase I/Ⅱ study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

CELF2-deficient mutations promote B-cell lymphoma development by inducing a germinal center B-cell fate

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory follicular lymphoma

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory diffuse large B-cell lymphoma

Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma (MCL) after receiving covalent bruton tyrosine kinase inhibitors (cBTKi) in China

Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)

Linperlisib Combined with CHOP Regimen Followed By Autologous Hematopoietic Stem Cell Transplantation and Linperlisib Monotherapy Maintenance for Newly Diagnosed Nodal T-Follicular Helper Cell Lymphoma Patients: A Phase II Trial

Safety and Efficacy of Iruplinalkib for Patients with Relapsed or Refractory (r/r) ALK+ Lymphoma: A Phase II Trial

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only